article

• A case-control study of betapapillomavirus infection and cutaneous squamous cell carcinoma in organ transplant recipients.
• A direct role for ATP1A1 in unconventional secretion of fibroblast growth factor 2.
• A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology.
• A novel peptide motif binding to and blocking the intracellular activity of the human papillomavirus E6 oncoprotein.
• A time-resolved live cell imaging assay to identify small molecule inhibitors of FGF2 signaling.
• ADP-ribosylation of actin by Clostridium perfringens iota toxin and turkey erythrocyte ADP-ribosyltransferase A: effects on profilin-regulated nucleotide exchange and ATPase activity.
• ADP-ribosyltransferase type A from turkey erythrocytes modifies actin at Arg-95 and Arg-372.
• Absence of SV40 antibodies or DNA fragments in prediagnostic mesothelioma serum samples.
• Active site mutation of the C3-like ADP-ribosyltransferase from Clostridium limosum--analysis of glutamic acid 174.
• Antibodies against Gag are diagnostic markers for feline foamy virus infections while Env and Bet reactivity is undetectable in a substantial fraction of infected cats.
• Antibody responses to 26 skin human papillomavirus types in the Netherlands, Italy and Australia.
• Are two doses of human papillomavirus vaccine sufficient for girls aged 15-18 years? Results from a cohort study in India.
• Automated high-throughput RNAi screening in human cells combined with reporter mRNA transfection to identify novel regulators of translation.
• Beta-papillomavirus DNA loads in hair follicles of immunocompetent people and organ transplant recipients.
• Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study.
• Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial.
• Comparison of the immunogenicity of Cervarix® and Gardasil® human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults.
• Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomaviruse types 16 and 18.
• Cytotoxic effects by microinjection of ADP-ribosylated skeletal muscle G-actin in PtK2 cells in the absence of Clostridium perfringens iota toxin.
• Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients.
• Design and Synthesis of Dihydroxamic Acids as HDAC6/8/10 Inhibitors.
• Determination of the binding affinity of different human papillomavirus E7 proteins for the tumour suppressor pRb by a plate-binding assay.
• Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate.
• E6/E7 expression of human papillomavirus types in cutaneous squamous cell dysplasia and carcinoma in immunosuppressed organ transplant recipients.
• Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7).
• Evaluation of different glutathione S-transferase-tagged protein captures for screening E6/E6AP interaction inhibitors using AlphaScreen.
• Evaluation of serological assays to monitor antibody responses to single-dose HPV vaccines.
• First Fluorescent Acetylspermidine Deacetylation Assay for HDAC10 Identifies Inhibitors of Neuroblastoma Cell Colony Growth That Increase Lysosome Accumulation
• Gln 63 of Rho is deamidated by Escherichia coli cytotoxic necrotizing factor-1.
• Glucosylation and ADP ribosylation of rho proteins: effects on nucleotide binding, GTPase activity, and effector coupling.
• HPV antibody detection by ELISA with capsid protein L1 fused to glutathione S-transferase.
• High-throughput pseudovirion-based neutralization assay for analysis of natural and vaccine-induced antibodies against human papillomaviruses.
• Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines.
• Human papillomavirus and posttransplantation cutaneous squamous cell carcinoma: A multicenter, prospective cohort study.
• Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin.
• Human papillomavirus type 16 E2- and L1-specific serological and T-cell responses in women with vulval intraepithelial neoplasia.
• Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice.
• Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study.
• Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination.
• Interaction of the Rho-ADP-ribosylating C3 exoenzyme with RalA.
• Loss of N-Glycanase 1 Alters Transcriptional and Translational Regulation in K562 Cell Lines.
• Modification of HPV 16 E7 genes: correlation between the level of protein expression and CTL response after immunization of C57BL/6 mice.
• Molecular basis of mRNA transport by a kinesin-1-atypical tropomyosin complex.
• Multicenter study of the association between betapapillomavirus infection and cutaneous squamous cell carcinoma.
• Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins.
• Neosynthesis and activation of Rho by Escherichia coli cytotoxic necrotizing factor (CNF1) reverse cytopathic effects of ADP-ribosylated Rho.
• New 7-methylguanine derivatives targeting the influenza polymerase PB2 cap-binding domain.
• Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines.
• Presence of DNA of human papillomavirus 16 but no other types in tumor-free tonsillar tissue.
• Prevalence and multiplicity of cutaneous beta papilloma viruses in plucked hairs depend on cellular DNA input.
• Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types.
• Recognition of 2'-O-methylated 3'-end of piRNA by the PAZ domain of a Piwi protein.
• Residues in the HIV-1 capsid assembly inhibitor binding site are essential for maintaining the assembly-competent quaternary structure of the capsid protein.
• Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated
• Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated.
• Serological association of beta and gamma human papillomaviruses with squamous cell carcinoma of the skin.
• Seroprevalence of 34 human papillomavirus types in the German general population.
• Small Molecule Inhibitors Targeting Tec Kinase Block Unconventional Secretion of Fibroblast Growth Factor 2.
• Small-molecule inhibition of MuRF1 attenuates skeletal muscle atrophy and dysfunction in cardiac cachexia.
• Small-molecule-mediated chemical knock-down of MuRF1/MuRF2 and attenuation of diaphragm dysfunction in chronic heart failure.
• Specific Inhibitors of HIV Capsid Assembly Binding to the C-Terminal Domain of the Capsid Protein: Evaluation of 2-Arylquinazolines as Potential Antiviral Compounds.
• Structural basis for targeting the chromatin repressor Sfmbt to Polycomb response elements.
• Suppression of non-specific binding in serological Luminex assays.
• Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials.
• The E6AP binding pocket of the HPV16 E6 oncoprotein provides a docking site for a small inhibitory peptide unrelated to E6AP, indicating druggability of E6.
• The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodies.
• The structural basis for cap binding by influenza virus polymerase subunit PB2.
• Tumor suppressive activity of a variant isoform of manganese superoxide dismutase released by a human liposarcoma cell line.
• Two-dose recommendation for Human Papillomavirus vaccine can be extended up to 18 years - updated evidence from Indian follow-up cohort study.